ReviewPrzeglad gastroenterologiczny2016
Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma.
Review in Przeglad gastroenterologiczny, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Use of Vascular Shunt at the Time of Pancreatectomy with Venous Resection: A Systematic Review.Cancers · 2024Review
- Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer.Frontiers in immunology · 2022Review
- Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2020Article
- HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation.Cancer cell international · 2020Article
- Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models.American journal of cancer research · 2019Article
- Cystic fluid neutrophil gelatinase-associated lipocalin (NGAL) concentration in differential diagnosis of pancreatic cystic lesions: a new factor enters the scene?Przeglad gastroenterologiczny · 2018Article
- PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation.Oncotarget · 2017Article
- Distal pancreatectomy with splenorenal shunt to preserve spleen in a cirrhotic patient.Annals of hepato-biliary-pancreatic surgery · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most aggressive and deadly malignancies. Despite better understanding of its biology and pathogenesis, contemporary treatment regimens are still insufficient. Along with the introduction of new treatment agents and combination therapy, the response rates are increasing, but these scores do not go with overall survival, and results are frequently conflicting. Therefore, contemporary medicine faces the challenge of expanding the knowledge base and practice on all grounds - pathology, factor risk, diagnosis, and finally surgical and palliative treatment of this disease. This paper provides a review of current adjuvant and neoadjuvant regimens and the role of experimental therapies in pancreatic ductal adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.